NCOA2 translocations have been described in various cancers such as acute myeloid leukemia (fusion with KAT6A), acute lymphoblastic leukemia (fusion with ETV6), mesenchymal chondrosarcoma (fusion with HEY1), and prostate and colon cancer, whereas ETV3 alterations have been reported in brain and breast cancer [5, 7]. Here, NCOA2 is linked to cancer.